AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
ATT.ST

Attendo AB (publ) (ATT.ST) fair value

Healthcare · Medical Care Facilities · Nasdaq Stockholm · Sweden
kr 114.80+0.17%
Market cap kr 16.1BNext earnings 2026-11-06Updated Oct 22, 2026
Add earnings to calendarGoogle
Our verdict
Trades 15% below our fair value
Price
kr 114.80
Model fair valueConfidence: good
kr 135
Model range
kr 58.38 to kr 209
Fair value kr 135
Price kr 115
5 models fit Attendo AB (publ) and they disagree: 1 of 5 land within 15% of the average.
Two or more of our models back this value.
Discount(i)Silver71
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, Graham number, and Dividend discount.
ACCE opinionAttendo AB (publ) (ATT.ST)
Fair value (5 models)
kr 135
ACCE price target
kr 126
Rating
Undervalued
Horizon
12 months
Fair value published on 22 Oct 2026, 13:04 CEST.
ACCE price target published on 23 Oct 2026, 01:53 CEST.
Price used: kr 115 at the close on 23 Oct 2026, 17:30 CEST.
Models: Discounted cash flow, P/E comparison, EV/EBITDA comparison, Graham number, and Dividend discount.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
14.8% below
+17.4% to fair value
ACCE score
63
out of 100
P/E
16.9x
forward 26.9x
1-year return
+62.1%
Dividend yield
0.79%

Attendo AB (publ) in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Attendo runs elder care, residential care homes and disability and psychiatric care services in the Nordics, Germany and the UK, with care delivered under long-term municipal and public contracts. The moat is the regulated, contract-based nature of that work: public payers are sticky, and operators with scale and quality records win repeat tenders. Revenue growth has slowed to 1.3%, which is the central issue, and the forward P/E of 26.9 against a trailing 17.3 implies the market expects earnings to fall, so a recovery in volumes or margins is what would justify a closer look. Operating margin of 9.4% against a 36.9% gross margin shows how much of the gross profit is absorbed by staff and overhead, so every point of margin recovered matters more than top-line growth at this stage. ROE of 18.7% is solid, but the thesis needs evidence that occupancy and wage cost trends are improving before the stock merits deeper work.

AI-assisted·How I use AIWritten Oct 23, 2026

Next results

Nov 6, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where ATT.ST's valuation models land
Price
kr 114.80
Model fair value
kr 135
Model range
kr 58.38 to kr 209
Fair value kr 135
Price kr 115
The price sits inside the model range.
Model
Fair value
Upside
Discounted cash flow
Dividend discount
EV/EBITDA comparison
Graham number
P/E comparison
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

No analyst coverage yet.
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Recent performance

1 week
-4.8%
1 month
-10.9%
3 months
+5.0%
6 months
+9.5%
YTD
+40.2%
1 year
+62.1%

Recommendation history, last 12 months

DateTypeNewPreviousPrice
23 Oct 2026, 01:53 CESTACCE price targetkr 126first publicationkr 115
22 Oct 2026, 13:04 CESTFair valuekr 135first publicationkr 117
22 Oct 2026, 13:04 CESTRatingFairly valuedfirst publicationkr 117

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

This security trades in SEK. Exchange-rate movements can increase or reduce the result in your own currency.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full ATT.ST page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth55Value68Quality52Momentum77Total63
Valuation
Trailing P/E
16.9x
Forward P/E
26.9x
PEG
0.14
P/B
3.42x
EV / Revenue
1.8x
Book value/sh
kr 37.19
Enterprise value
kr 33.4B
Profitability
ROE
18.7%
FCF yield
16.47%
ROIC
3.0%
Health and risk
Debt / equity
3.02
Dividend yield
0.79%
Beta
0.95

Price

+47.7% · 1Y

Ask anything about ATT.ST

Answered from Attendo AB (publ) fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 100% of peers
low 16.9x16.9xhigh 44.7x
ROEbetter than 100% of peers
low 2%19%high 19%
Div yieldbetter than 67% of peers
low 0.0%0.8%high 4.5%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
ATT.ST Attendo AB (publ)kr 114.80kr 13515% below16.9x18.7%5263
SIA.TO Sienna Senior Living Inc.C$20.53C$1186% above38.7x6.7%4250
ARDT Ardent Health Inc. Common Stock$12.27$1625% below22.7x10.0%4753
AMN AMN Healthcare Services Inc$48.01$7133% below17.9x15.6%5273
ASTH Astrana Health Inc. Common Stock$37.45--44.7x6.9%3572
AMBEA.ST Ambea AB (publ)kr 181.80kr 21716% below19.1x15.5%4768
SGRY Surgery Partners Inc. Common Stock$15.75$1052% above-2.3%3343

Sector report card

Where ATT.ST ranks against its sector peers on each metric.

Computing percentiles…